TRACON Pharmaceuticals

$8.15
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.21 (-2.51%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell TCON and other stocks, options, and ETFs commission-free!

About TCON

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA. The listed name for TCON is TRACON Pharmaceuticals, Inc. Common Stock.

CEO
Charles P. Theuer
Employees
19
Headquarters
San Diego, California
Founded
2004
Market Cap
132.09M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
528.53K
High Today
$8.69
Low Today
$7.50
Open Price
$8.31
Volume
637.59K
52 Week High
$12.20
52 Week Low
$0.95

TCON Earnings

-$1.66
-$1.16
-$0.67
-$0.17
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.41 per share
Actual
-$0.31 per share
Replay Earnings Call

You May Also Like

GUNR
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure